What is the antibody response to Sinopharm boosters against Omicron?

Question

Accepted Answer

Antibody Response to Sinopharm Boosters Against Omicron Sub-variants Remains Limited

A study published in The Lancet Infectious Diseases indicates that neutralising antibody levels against certain Omicron sub-variants are only partially restored by Sinopharm booster shots, following two initial doses of the BBIBP-CorV vaccine. The research, which focused on antibody detection rather than overall disease prevention, observed that while boosters did increase neutralising activity, it remained considerably lower than ideal against sub-variants like BA.2.12.1 and BA.4/BA.5.
Reduced Neutralising Activity After Initial Dosing

Following a two-dose regimen of the Sinopharm BBIBP-CorV vaccine, neutralising antibody activity against Omicron sub-variants such as BA.2.12.1 and BA.4/BA.5 was found to be either undetectable or minimally present among 25 participants. This suggests that the primary vaccination series alone provided limited protection against these specific strains of the virus.
Partial Restoration with BBIBP-CorV Booster

When participants received a booster shot of the same BBIBP-CorV vaccine after completing the initial two doses, neutralising activity against the Omicron sub-variants showed improvement. However, this activity was only detected in a relatively small percentage of subjects, ranging from 24 to 48 per cent of the 25 individuals studied.
Modest Increase with Heterologous Booster

A slight improvement in neutralising antibody detection was observed when participants received a third dose from a different manufacturer, specifically a vaccine from Chongqing Zhifei Biological Products. In a separate group of 30 subjects, this heterologous booster approach resulted in neutralising activity being observed in 30 to 53 per cent of individuals.
Efficacy Against Disease Not Assessed

It is important to note that this study specifically examined neutralising antibody responses. The research did not assess the overall efficacy of the Sinopharm boosters, which typically measures how well the vaccines reduce the risk of symptomatic Covid-19 disease or death. Such efficacy data is generally derived from larger clinical trials.

Reading history

Hide →

This history is cleared when the page is closed.

What is the antibody response to Sinopharm boosters against Omicron?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends